Form 8-K PLURISTEM THERAPEUTICS For: Jun 02

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 2, 2021 (June 2, 2021)

 

PLURISTEM THERAPEUTICS INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada		001-31392		98-0351734
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel		3508409
(Address of Principal Executive Offices)		(Zip Code)

 

011 972 74 710 7171

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		PSTI		The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 1, 2021, Pluristem Therapeutics Inc., or the Company, held its 2021 Annual Meeting of Stockholders, or the 2021 Annual Meeting. The results of stockholder voting at the 2021 Annual Meeting are set forth below:

 

Proposal No. 1 — Election of Directors

 

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

 

Director Name		For				Against				Abstain				Broker Non-Votes
Zami Aberman			9,921,167				173,259				10,617				5,220,994
Mark Germain			5,755,350				4,338,868				10,825				5,220,994
Moria Kwiat			6,001,421				4,093,061				10,561				5,220,994
Maital Shemesh-Rasmussen			9,988,263				104,990				11,794				5,220,990
Rami Levi			9,905,005				189,258				10,788				5,220,985
Doron Shorrer			5,717,794				4,376,450				10,795				5,220,998
Yaky Yanay			9,918,727				175,815				10,501				5,220,994

 

Proposal No. 2 — Ratification of the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021.

 

For		Against		Abstain		Broker Non-Votes
15,115,914		193,797		16,326		N/A

 

Proposal No. 3 —Approval, by a nonbinding advisory vote, of the compensation of the Company’s named executive officers.

 

For		Against		Abstain		Broker Non-Votes
8,961,227		1,111,925		31,891		5,220,994

 

The results reported above are final voting results.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	PLURISTEM THERAPEUTICS INC.
Date: June 2, 2021	By:	/s/ Chen Franco-Yehuda
	Name:	Chen Franco-Yehuda
	Title:	Chief Financial Officer

 

 

2

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• iZafe Group's Quarterly Report January-March 2024
• Konsolidator maintains its financial expectations for 2024
• Information relating to the total number of voting rights and shares making up the share capital at 26 April 2024 – post blocs acquisition by the Consortium